Esketamine nasal spray, approved by the FDA in 2019 for treatment-resistant depression (TRD) and later for major depressive disorder (MDD) with suicidal ideation, represented a paradigm shift in psychiatric treatment. However, six years post-approval, its clinical application remains fraught with uncertainties. While its rapid-acting antidepressant effects are lauded, concerns persist regarding long-term efficacy, safety, accessibility, and appropriate patient selection.
Efficacy Beyond the Acute Phase
Esketamine’s mechanism of action—an NMDA receptor antagonism leading to enhanced synaptic plasticity—distinguishes it from conventional antidepressants. Clinical trials have demonstrated its efficacy in rapidly reducing depressive symptoms, often within hours (Daly et al., 2019). However, data on sustained benefits remain inconclusive. Many patients experience relapse despite ongoing treatment, raising questions about optimal dosing strategies and the neurobiological underpinnings of its waning effects. Longitudinal studies are needed to clarify its durability and potential neuroadaptive changes over extended use.
Safety and Abuse Potential
As a derivative of ketamine, esketamine carries the risk of dissociation, cognitive impairment, and abuse liability. Although its intranasal delivery under medical supervision aims to mitigate misuse, reports of nonmedical use are emerging (Strassman, 2022). Additionally, long-term effects on cognition remain unclear. Patients undergoing prolonged esketamine therapy require rigorous monitoring, yet guidelines for cognitive assessment and discontinuation protocols remain underdeveloped.
Accessibility and Ethical Considerations
Despite its promise, esketamine is not universally accessible. Its high cost, coupled with stringent administration requirements—restricted to certified healthcare settings—renders it impractical for many individuals with TRD. Insurance coverage remains inconsistent, disproportionately affecting marginalized populations. Ethical dilemmas arise when a potentially life-saving treatment is available but financially out of reach. Addressing these disparities necessitates policy interventions and broader insurance mandates.
Patient Selection and Biomarkers
Identifying patients who will derive the most benefit from esketamine remains an enigma. While some individuals experience profound remission, others show minimal response. Biomarker research, including genetic, inflammatory, and neuroimaging studies, may help stratify patient populations, yet no definitive predictive model exists (Kadriu et al., 2021). Personalized medicine approaches could optimize treatment outcomes and minimize unnecessary exposure to potential risks.
Conclusion
Six years into its clinical use, esketamine remains a double-edged sword—offering hope yet raising pressing questions. Future research must address its long-term efficacy, safety, and accessibility while refining patient selection criteria. Without these answers, esketamine’s full therapeutic potential remains unrealized.
Reference:
Daly, E. J., et al. (2019). Efficacy and safety of esketamine in treatment-resistant depression. New England Journal of Medicine, 380(13), 1243-1253.
Strassman, R. (2022). The resurgence of ketamine: Implications for psychiatric practice. Journal of Psychopharmacology, 36(5), 327-335.
Kadriu, B., et al. (2021). Identifying biomarkers for response to ketamine in depression. Molecular Psychiatry, 26(9), 4727-4741.